Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Hookipa Pharma Inc (HOOK)
NASDAQ:HOOK
Holding HOOK?
Track your performance easily
HOOK Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.10 - $11.31
Previous Close$4.62
Volume42.84K
Average Volume (3M)38.11K
Market Cap
$155.46M
Enterprise Value$83.21M
Total Cash (Recent Filing)$77.15M
Total Debt (Recent Filing)$4.90M
Price to Earnings (P/E)―
Beta1.14
Next Earnings
Nov 13, 2024EPS Estimate
-$1.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.62
Shares Outstanding12,054,539
10 Day Avg. Volume25,584
30 Day Avg. Volume38,107
Standard Deviation0.22
R-Squared0.04
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)0.65
Price to Sales (P/S)1.10
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.60
Enterprise Value/Gross Profit4.13
Enterprise Value/Ebitda-1.75
Forecast
1Y Price Target
$19.50Price Target Upside316.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Hookipa Pharma News
PremiumCompany Announcements
Hookipa Pharma Announces Board Restructuring and Appointments
PremiumCompany Announcements
Hookipa Pharma Announces Executive Reshuffle and Board EnhancementsBulls Say, Bears Say
Bulls Say
Clinical TrialsThe pivotal Phase 2/3 trial for eseba-vec combined with pembrolizumab in oropharyngeal squamous cell carcinoma has been aligned with the FDA, potentially leading to accelerated approval after an interim analysis.
Financial StabilityHOOKIPA Pharma reported having $77M in cash, which is projected to be sufficient to support operations into the second half of 2025.
Treatment EfficacyHB-200 achieved an overall response rate of 37% in head and neck cancer, with impressive durability and three complete responses from 17 high PD-L1 patients.
Bears Say
CompetitionPetosemtamab could be a competent competitor.
Market ReactionHookipa shares have generally moved lower following the ASCO abstract release, likely on competitor results.
Product LaunchMove estimated launch for HB-200 to 2028, delaying market entry.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
HOOK FAQ
What was Hookipa Pharma Inc’s price range in the past 12 months?
Hookipa Pharma Inc lowest stock price was $4.10 and its highest was $11.31 in the past 12 months.
What is Hookipa Pharma Inc’s market cap?
Currently, no data Available
When is Hookipa Pharma Inc’s upcoming earnings report date?
Hookipa Pharma Inc’s upcoming earnings report date is Nov 13, 2024 which is in 54 days.
How were Hookipa Pharma Inc’s earnings last quarter?
Hookipa Pharma Inc released its earnings results on Aug 08, 2024. The company reported -$1.52 earnings per share for the quarter, missing the consensus estimate of -$1.252 by -$0.268.
Is Hookipa Pharma Inc overvalued?
According to Wall Street analysts Hookipa Pharma Inc’s price is currently Undervalued.
Does Hookipa Pharma Inc pay dividends?
Hookipa Pharma Inc does not currently pay dividends.
What is Hookipa Pharma Inc’s EPS estimate?
Hookipa Pharma Inc’s EPS estimate is -$1.28.
How many shares outstanding does Hookipa Pharma Inc have?
Hookipa Pharma Inc has 9,655,022 shares outstanding.
What happened to Hookipa Pharma Inc’s price movement after its last earnings report?
Hookipa Pharma Inc reported an EPS of -$1.52 in its last earnings report, missing expectations of -$1.252. Following the earnings report the stock price went down -7.115%.
Which hedge fund is a major shareholder of Hookipa Pharma Inc?
Among the largest hedge funds holding Hookipa Pharma Inc’s share is Baker Bros Advisors LP. It holds Hookipa Pharma Inc’s shares valued at 5M.
---
Hookipa Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$19.50 (316.67% Upside)
$19.50 (316.67% Upside)
Blogger Sentiment
Bullish
HOOK Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 961.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.9%
Last 30 Days ▼ 8.1%
Last 30 Days ▼ 8.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.37%
12-Months-Change
Fundamentals
Return on Equity
-48.99%
Trailing 12-Months
Asset Growth
-34.57%
Trailing 12-Months
Company Description
Hookipa Pharma Inc
HOOKIPA Pharma, Inc. engages in the development of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary its arenavirus platform that is designed to reprogram the body's immune system. Its product include VaxWace, a replication-deficient viral vector; and TheraT, a replication-attenuated viral vector, are designed to induce robust antigen specific CD8+ T cells and pathogen-neutralizing antibodies. The company was founded by Rolf Zinkernagel, Andreas Bergthaler, Lukas Flatz, and Daniel Pinschewer in 2011 and is headquartered in New York, NY.
---
HOOK Company Deck
---
HOOK Earnings Call
Q4 2023
0:00 / 0:00
---
HOOK Stock 12 Month Forecast
Average Price Target
$19.50
▲(316.67% Upside)
Technical Analysis
Best Analysts Covering HOOK
1 Year
1 Year Success Rate
4/25 ratings generated profit
1 Year Average Return
-38.09%
reiterated a buy rating 4 months ago
Copying Brian Abrahams's trades and holding each position for 1 Year would result in 16.00% of your transactions generating a profit, with an average return of -38.09% per trade.
---